Loading company…
Starmab develops anti-infective biologics.
Starmab researches anti-infective macromolecules targeting bacteria, fungi and viruses. Its products include XJ101 for MRSA bloodstream infection and XJ103 for Streptococcus pneumoniae. Founded in 2020, the company is based in Suzhou, China. It raised CNY 100 million in series A funding in February 2023 and closed venture funding in March 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in